ClinVar Miner

Submissions for variant NM_000540.3(RYR1):c.14474G>A (p.Arg4825His)

gnomAD frequency: 0.00001  dbSNP: rs193922875
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001040954 SCV001204547 pathogenic RYR1-related disorder 2024-01-26 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 4825 of the RYR1 protein (p.Arg4825His). This variant is present in population databases (rs193922875, gnomAD 0.006%). This missense change has been observed in individual(s) with autosomal dominant malignant hyperthermia susceptibility (PMID: 36283893). ClinVar contains an entry for this variant (Variation ID: 839243). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RYR1 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg4825Cys amino acid residue in RYR1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11709545, 17204937, 35081925, 35428369). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV002481884 SCV002794485 uncertain significance Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome 2021-09-14 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV003130110 SCV003814453 uncertain significance not provided 2022-11-16 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.